Results 181 to 190 of about 97,218 (302)

Assessing Cytochrome P450 Drug Interaction Risk for Dordaviprone Using Physiologically Based Pharmacokinetic Modeling

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 10, Page 1695-1704, October 2025.
ABSTRACT A physiologically based pharmacokinetic (PBPK) model was developed and verified for dordaviprone, a small molecule with antitumor effects in glioma patients. The model was applied to assess the drug–drug interaction (DDI) potential of dordaviprone as a victim of CYP3A4 inhibitors and inducers, and as a perpetrator of CYP3A4, CYP2C8, CYP2D6 ...
Swati Jaiswal   +6 more
wiley   +1 more source

Physiologically Based Pharmacokinetic Modeling of Valemetostat to Inform Dose Recommendations When Coadministered With CYP3A/P‐gp Modulators

open access: yesClinical and Translational Science, Volume 18, Issue 10, October 2025.
ABSTRACT Valemetostat tosylate (valemetostat) is an oral, potent, selective dual inhibitor of enhancer of zeste homolog (EZH)2 and EZH1, approved in Japan for the treatment of relapsed/refractory adult T‐cell leukemia/lymphoma and peripheral T‐cell lymphoma.
Akiko Watanabe   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy